| Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. | |
| | |
MedLine Citation:
|
PMID: 20150324 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
AIMS: In ISAR-REACT 3, 30-day outcomes in 4570 biomarker negative patients undergoing percutaneous coronary intervention (PCI) > or =2 h after pre-treatment with 600 mg of clopidogrel revealed less bleeding with bivalirudin compared with unfractionated heparin, but no difference in 30-day net clinical benefit. The objective of the present analysis was to assess the impact of bivalirudin vs. heparin on 1-year outcomes in ISAR-REACT 3. METHODS AND RESULTS: The primary outcome for this analysis was the composite of death, myocardial infarction, or target vessel revascularization 1 year after randomization. The composite of death or myocardial infarction was a secondary outcome. At 1 year, the primary outcome occurred in 17.1% of patients assigned to bivalirudin vs. 17.5% assigned to heparin [hazard ratio (HR), 0.98; 95% confidence interval (CI), 0.86-1.13; P = 0.816]. The combined incidence of death or myocardial infarction was 7.7% in the bivalirudin group vs. 6.7% in the heparin group (HR, 1.15; 95% CI, 0.93-1.43; P = 0.200). The mortality rate was 1.9% in the bivalirudin group and 1.7% in the heparin group (HR, 1.10; 95% CI, 0.71-1.70; P = 0.667). At 1 year, no significant differences in the primary outcome were observed with bivalirudin and heparin in any of the subgroups analysed. CONCLUSION: Bivalirudin and unfractionated heparin during PCI provide comparable outcomes at 1 year in biomarker negative patients undergoing PCI after pre-treatment with 600 mg of clopidogrel. Clinical trial registration information: URL www.clinicaltrials.gov; Unique identifier NCT00262054. |
| | |
Authors:
|
Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz-Josef Neumann; Katrin A Birkmeier; Sebastian Kufner; Gert Richardt; Peter B Berger; Albert Schömig; Adnan Kastrati; |
Related Documents
:
|
9894704 - Changing prescribing behaviour: early low dose aspirin in suspected acute myocardial in... 9439754 - Low-molecular-weight heparins and unstable angina--current perspectives. 10945524 - Aspirin renography and captopril renography in the diagnosis of renal artery stenosis. 16370924 - Tirofiban for the treatment of ischaemic stroke. 22093694 - Moderate tricuspid regurgitation with left-sided degenerative heart valve disease: to r... 7750354 - Acute, reversible left ventricular dysfunction in status asthmaticus. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-02-11 |
Journal Detail:
|
Title: European heart journal Volume: 31 ISSN: 1522-9645 ISO Abbreviation: Eur. Heart J. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-03-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: England |
Other Details:
|
Languages: eng Pagination: 582-7 Citation Subset: IM |
Affiliation:
|
Deutsches Herzzentrum, Technische Universität, Munich, Germany. schulzs@dhm.mhn.de |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00262054 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Comments/Corrections | |
Comment In:
|
Eur Heart J. 2010 Mar;31(5):522-4
[PMID:
20150323
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: RNA-targeted splice-correction therapy for neuromuscular disease.
Next Document: Endocrine treatment of transsexual persons: An Endocrine Society clinical practice guideline - comme...